How Biotechs Are Using Microbiome Therapies to Treat Chronic Disease

This episode explores how biotech startups are engineering the human microbiome to treat chronic diseases like inflammatory bowel disease and metabolic disorders. Lucas and Luna break down the science behind microbiome therapies, focusing on a case study of a company that recently published phase 2 data for a live biotherapeutic product targeting ulcerative colitis. They discuss the challenges of manufacturing live bacteria as drugs, the regulatory path for these novel treatments, and why big pharma is paying attention. Specific numbers include the size of the microbiome therapeutics market projected to reach $9.5 billion by 2030 and the success rate of phase 2 trials in this space. The hosts also touch on the role of AI in analyzing microbiome data to identify therapeutic targets. No prior episodes have covered microbiome therapies, making this a fresh angle on the intersection of biology and technology. #MicrobiomeTherapies #BiotechStartups #ChronicDisease #UlcerativeColitis #LiveBiotherapeuticProducts #MicrobiomeEngineering #Phase2Trials #IBD #MetabolicDisorders #DrugDevelopment #FDAApprovals #AIinBiotech #GutMicrobiome #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo